Xing Wang

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Likun Ren · 2 shared papers, 2024 · strength 0.42
   • Paper TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, inv… DOI 10.1016/j.cellsig.2024.111227↗
   • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
2. Songbai Liu · 2 shared papers, 2024 · strength 0.42
   • Paper TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, inv… DOI 10.1016/j.cellsig.2024.111227↗
   • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
3. Yaozhen Pan · 2 shared papers, 2024 · strength 0.42
   • Paper TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, inv… DOI 10.1016/j.cellsig.2024.111227↗
   • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
4. Xiaobin Fei · 2 shared papers, 2024 · strength 0.42
   • Paper TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, inv… DOI 10.1016/j.cellsig.2024.111227↗
   • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
5. Yongjia Gao · 2 shared papers, 2024 · strength 0.42
   • Paper TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, inv… DOI 10.1016/j.cellsig.2024.111227↗
   • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
6. Chunlu Tan · 2 shared papers, 2020–2023 · strength 0.33
   • Paper Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarci… DOI 10.3390/jcm12030756↗
   • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗
7. Qingquan Tan · 2 shared papers, 2020–2023 · strength 0.33
   • Paper Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarci… DOI 10.3390/jcm12030756↗
   • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗
8. Xubao Liu · 1 shared paper, 2023 · strength 0.22
   • Paper Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarci… DOI 10.3390/jcm12030756↗
9. Guanhua Chen · 1 shared paper, 2023 · strength 0.22
   • Paper Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarci… DOI 10.3390/jcm12030756↗
10. Yonghua Chen · 1 shared paper, 2023 · strength 0.22
    • Paper Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarci… DOI 10.3390/jcm12030756↗
11. Peng Liu · 1 shared paper, 2024 · strength 0.21
    • Paper PELI1: key players in the oncogenic characteristics of pancreatic Cancer. DOI 10.1186/s13046-024-03008-9↗
12. Xu-Bao Liu · 1 shared paper, 2020 · strength 0.11
    • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗
13. Yuqiang Shan · 1 shared paper, 2020 · strength 0.11
    • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗
14. Hao Zhang · 1 shared paper, 2020 · strength 0.11
    • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗
15. Nengwen Ke · 1 shared paper, 2020 · strength 0.11
    • Paper MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. DOI 10.1186/s12935-020-1146-x↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.